LLYELI LILLY & Co

NYSE lilly.com


$ 948.24 $ 14.26 (1.53 %)    

Friday, 12-Jul-2024 15:59:58 EDT
QQQ $ 494.79 $ 2.89 (0.59 %)
DIA $ 400.37 $ 2.69 (0.68 %)
SPY $ 559.91 $ 3.51 (0.63 %)
TLT $ 93.88 $ 0.40 (0.43 %)
GLD $ 223.10 $ -0.14 (-0.06 %)
$ 948.4
$ 935.00
$ 0.00 x 0
$ 0.00 x 0
$ 935.00 - $ 950.34
$ 431.12 - $ 950.79
2,315,131
na
857.16B
$ 0.57
$ 139.64
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-presence---goldman-sachs

Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with...

 using-ozempic-zepbound-or-other-weight-loss-drugs-inform-doctors-before-anesthesia-or-surgery-european-medicines-agency-issues-advisory

EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory...

 novo-nordisks-miracle-weight-loss-drug-ozempic-linked-to-48-lower-risk-of-dementia-study-finds

Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other ...

 eli-lilly-novo-nordisk-shares-dip-as-pfizer-ramps-up-diabetes-drug-competition

Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by compe...

 bernie-sanders-targets-high-prices-of-ozempic-and-wegovy-in-us

Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broa...

 berenberg-maintains-buy-on-eli-lilly-and-co-raises-price-target-to-1000

Berenberg analyst Kerry Holford maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $850 to $1...

 jp-morgan-maintains-overweight-on-eli-lilly-and-co-raises-price-target-to-1000

JP Morgan analyst Chris Schott maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and raises the price target from $900...

 jim-cramer-identifies-eight-companies-eyeing-trillion-dollar-club--elon-musks-tesla-eli-lilly-top-contenders

Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's T...

 barclays-maintains-overweight-on-eli-lilly-and-co-raises-price-target-to-1025

Barclays analyst Carter Gould maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and raises the price target from $913 ...

 eli-lilly-announces-cfo-change
Eli Lilly Announces CFO Change
07/10/2024 19:35:39

Shares of Eli Lilly And Company (NYSE: LLY) are moving higher on Wednesday. Here's what you need to know.

Core News & Articles

The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating...

 only-25-patients-stick-with-novo-nordisks-wegovy-or-ozempic-after-2-years-a-study-shows-company-calls-data-insufficient

A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on t...

Core News & Articles

https://www.dailymail.co.uk/health/article-13620101/ozempic-quitting-patients-weight-loss-effects.html?ns_mchannel=rss&ns_c...

 eli-lillys-32b-morphic-deal-is-crucial-has-strategic-merit-despite-investor-attention-on-obesity-analyst

Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and ...

 sp-500-closes-at-record-high-ahead-of-inflation-data-fear--greed-index-remains-in-neutral-zone

The CNN Money Fear and Greed index slightly decreased, remaining in Neutral zone. US stocks mixed, with S&P 500 at record h...

 eli-lillys-mounjaro-outpaces-novo-nordisks-ozempic-in-weight-loss-effectiveness-study-shows

Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients o...